Saturday, 28 May, 2022
Advertisement
TopicCovishield

Topic: Covishield

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

Mohana Basu -
CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Purva Chitnis -
Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Abantika Ghosh -
Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Payal Banerjee -
Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Payal Banerjee -
Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

Not allowing Covishield, Covaxin retail sale meaningless. Indians need vaccines and boosters

ThePrint Team -
ThePrint view on the most important issues, instantly.

Covishield shows increased antibody response to Omicron after 3rd dose: AstraZeneca

Aditi Khanna -
Preliminary data released by AstraZeneca shows Vaxzevaria vaccine, administered in India as Covishield, increased immune response to Beta, Delta, Alpha, Gamma variants after third dose.

No trial data on 3 shots of Covaxin, as precaution dose begins from next Monday

Abantika Ghosh -
Trial on third Covaxin shot ongoing, results to be out soon, says Bharat Biotech. ICMR officials say 9-month interval based on studies that show antibodies last 6-13 months.

Govt says no Covaxin supply issue: 5 cr doses with states, 10 cr more coming in next 2 months

Abantika Ghosh -
Only Covaxin will be used for vaccinating an estimated 7.4 crore 15-18-year-olds, so finding a slot for the first shot of the indigenous vaccine could get more difficult.

Booster dose of Covishield can increase antibody levels against Omicron, Oxford study says

Mohana Basu -
Antibody levels against Omicron were higher in people who had taken a 3rd Covishield dose than in people who’d had other Covid variants, found a preprint study by Oxford researchers.
123...14Page 1 of 14

On Camera

YourTurn

Opinion

Economy

Representational image of cryptocurrencies | Pizabay

What are UST & Luna and why the fall of 2 ‘stablecoins’ led to a crypto crash in India

Shubham Batra -
Along with crash in value of UST and Luna coins, Indian market for crypto assets also reeling under strict control imposed by government, with the imposition of TDS on all crypto transactions.

Defence

NSA Ajit Doval with NSAs from the other countries at the meeting at Dushanbe, Tajikistan | Photo: Courtesy the NSA's office

NSA Ajit Doval pushes for ‘terror free’ Afghanistan, says India stands with Afghan people

Snehesh Alex Philip -
Doval's comments came at 4th Regional Security Dialogue on Afghanistan attended by national security advisors from Tajikistan, India, Russia, Kazakhstan, Uzbekistan, Iran, Kyrgyzstan & China.

National Interest

Why it’s obscene to tell Ukraine to give in & how war-upended global balance of power brings openings for India

Shekhar Gupta -
Global order is in flux, and India is being wooed by all. It opens up economic, strategic & military possibilities unimaginable till recently. It is for India to take this opportunity.

Follow us

Copyright © 2022 Printline Media Pvt. Ltd. All rights reserved.

×